After the impact of the epidemic disappeared in 2023, the pharmaceutical industry is facing a critical turning point. Industry policy and the competitive environment of enterprises are looking for a new balance between change and change, and it is likely to set the tone for a long time to come.
But we can still see that positive factors in the pharmaceutical industry are being born. The largest buyer in the pharmaceutical industry: medical insurance ** has released warmth since the second half of last year, several phenomenal drugs have ignited the public's enthusiasm for pharmaceutical innovation, and capital investment in the pharmaceutical industry has gradually recovered, which are all favorable aspects of the sustainable development of the pharmaceutical industry.
As a solid watchman of the pharmaceutical industry, the Health Knowledge Bureau has been recording the development of the industry from different perspectives at multiple levels such as policies, industries, and companies, working hard for good exploration, and appealing for the demands of the industry. Every year, the "Star List of the Year" invites authoritative experts in the industry to select the most noteworthy enterprises, entrepreneurs, products and operation practices in this year from multiple dimensions, leaving our mark in the booming pharmaceutical industry.
This year is the fourth edition of the "On Health - Annual Star List" series of activities, after getting rid of the haze of the new crown, we plan to organize an offline star list conference later on the basis of the previous list, so stay tuned!
Rankings are in alphabetical order by company name).
Wang Lei - AstraZeneca
Reason for selection:
As a leader who grew up in China, Wang Lei has a deep insight and unique understanding of China's healthcare industry. Under his leadership, AstraZeneca has not only become the largest pharmaceutical company in the Chinese market in terms of sales for many years, but has also been deeply integrated into the Chinese pharmaceutical industry.
In 2023, AstraZeneca will close seven deals with Chinese innovative pharmaceutical companies, totaling billions of dollars; A total of more than 20 Chinese pharmaceutical companies have reached cooperation to promote their products abroad; It has invested more than 1.1 billion US dollars in Qingdao, Wuxi, Taizhou and other places to establish production bases, and set up R&D centers in Hong Kong and other places.
Jean-Christophe Pointeau-Pfizer
Reason for selection:
In September 2021, Jean-Christophe Pointeau became the head of Pfizer China, as a Frenchman with a special affection for China, over the past two years, under his leadership and promotion, a total of 17 innovative products of Pfizer have been approved for marketing in China, which has broken the record of Pfizer China and created history in terms of speed and quantity.
It is Jean-Christophe Pointeau's commitment and responsibility to patients that has turned the "impossible" into a "possible", allowing thousands of Chinese patients to change their lives due to the convenience and accessibility of innovative medicines.
Gu Yushao - Medtronic
Reason for selection:
Gu Yushao attaches great importance to Medtronic's development in China, and since serving as the president of Greater China, he has continuously increased local innovation and development, and has successfully introduced more than 700 global innovative products, and has successively established advanced manufacturing bases in Shanghai, Chengdu, Changzhou and other places to realize the localization of high-quality products R&D and production.
Gu Yushao led the establishment of "Medtronic China**" to support Chinese start-ups to go international and help local innovation and sustainable development.
Zhang Wei-Merck
Reason for selection:
Zhang Wei led Merck China's healthcare business to seize 2023, a key year for the development of the pharmaceutical industry, and return to growth. Merck is committed to becoming a global specialty drug innovator, and in 2023, it not only introduced new blockbuster products, but also reached a number of strategic cooperation with leading domestic pharmaceutical companies such as Hengrui Pharmaceutical and Abbisko Pharmaceutical in the development and commercialization of innovative drugs.
Zhang Wei has formulated a five-year strategic plan for Merck HealthCare in China, determined to accelerate the introduction of innovative products, actively cooperate with local partners, promote pharmaceutical innovation and compliance construction, and contribute to the high-quality development of China's pharmaceutical industry.
Ying Zhang-Novartis
Reason for selection:
Ying Zhang led Novartis China to complete its strategic transformation in 2023, strengthening its focus on innovative drugs, four core areas and five key technology platforms, and maintaining a high growth momentum of its business.
In the past year, Novartis has promoted a major investment in radioligand** in China, and expanded its portfolio of kidney disease products through the acquisition of Chinese biopharmaceutical companies.
Liu Fengjiang-Shi Huida
Reason for selection:
In 2023, Liu Fengjiang led Shi Huida to buck the trend and bravely face industry challenges, not only made a comprehensive breakthrough in the three major terminal markets, but also exceeded expectations in sales, ranking firmly in the list of "Top 100 Enterprises in China's Pharmaceutical Industry".
Liu Fengjiang led the team to seek breakthroughs in the predicament, actively laid out the research and development of new drugs with independent intellectual property rights, and created the image of the leading brand of local original drugs of Shihuida Pharmaceutical. At the same time, Liu Fengjiang actively deployed public welfare undertakings and contributed to the construction of a healthy China through voluntary public welfare projects for the prevention and treatment of chronic diseases and safe drug use.